Overview

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label dose escalation trial using ABI-007 plus carboplatin.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel